Community data
GLP-1 side effect registry
An open, anonymous registry for real side effects on semaglutide and tirzepatide. We're opening this with zero entries on purpose. The numbers you see here will always be real, because we'll never seed this with fake reports.
Reviewed by the FormBlends Medical Review Team. Last reviewed .
0
Reports so far
20
Reports required before an aggregate page goes live
60s
Average time to submit
Why this exists
Clinical trials for GLP-1s enrolled thousands of people over 68 to 72 weeks. The STEP 1 trial (Wilding et al., NEJM, 2021) and the SURMOUNT trials (Jastreboff et al., NEJM, 2022) captured the main safety signals, but a 68-week window misses slow patterns. Hair changes at month 6. Sleep shifts at month 9. What happens when you taper.
Post-market data lives in FDA MedWatch and the FDA Adverse Event Reporting System, but MedWatch is hard to submit to and the published aggregate is lagged by quarters. This registry is built to fill that gap with fast, structured input from real patients.
What the registry captures
| Field | Required? | Why we ask |
|---|---|---|
| Medication (semaglutide / tirzepatide) | Yes | Separates signals between the two compounds |
| Dose (mg) | Yes | Many side effects are dose-dependent |
| Week on therapy | Yes | Timing is the single biggest pattern |
| Severity (1 to 5) | Yes | Lets us distinguish annoyance from crisis |
| Effect category + free text | Yes | Structured for aggregation, free text for nuance |
| Age bracket, sex at birth | No | Helps find demographic patterns when you opt in |
How it works
Report anonymously
Three quick steps. Medication, side effect, optional demographics. Under 60 seconds.
Our team reviews it
Every report is screened for spam and inappropriate content before it joins the aggregate dataset.
Patterns go public at n = 20
Once 20 reports exist for a medication and effect pair, we publish aggregate breakdowns by dose, week, and severity.
FAQ
Why does the registry show zero reports?
Because that's the real number. We're opening this registry with zero entries on purpose. The data you see here will always be real, because we will never seed it with fake reports. The first 100 reports will come from real patients, and you can be one of them.
What counts as a side effect I should report?
Anything you noticed after starting or changing a GLP-1. That includes the common ones like nausea, constipation, fatigue, and injection-site reactions, and the less common ones like mood changes, hair shedding, or gallbladder symptoms. The FDA Drug Safety Communications page at fda.gov tracks major signals, but individual patterns still matter.
Is the report really anonymous?
Yes. We don't store IP addresses or cookies with your report. You enter a medication, dose, week on therapy, severity on a 1 to 5 scale, and an effect category. Age bracket and sex at birth are optional. Nothing links back to you.
How is this different from FDA MedWatch?
FDA MedWatch is the official adverse event reporting system and we recommend using it for serious events. Our registry is lighter-weight and built for patterns the FDA doesn't publish openly. You can submit to both. FDA MedWatch is at fda.gov/safety/medwatch.
When will aggregate pages go live?
Per medication and effect combination, we publish aggregate breakdowns once we have at least 20 reports for that pair. Smaller counts are too noisy to draw any conclusion from. Our sitemap only includes pages that have cleared that 20-report floor.
How many US adults are even on a GLP-1?
KFF's Health Tracking Poll (May 2024) estimated 12 percent of US adults had ever used a GLP-1, with about 6 percent currently taking one. That's a large enough population that real-world side effect data can fill in what short clinical trials missed.
Related reading
What Is GLP-1? The Gut Hormone Behind Ozempic, Wegovy, and Modern Weight-Loss Medicine
GLP-1 is a gut hormone that controls hunger, blood sugar, and gastric emptying. Here's what GLP-1 means, how the medications work, and what to expect.
What Is Liraglutide? The Daily GLP-1 Behind Victoza and Saxenda, Explained
Liraglutide is a daily GLP-1 medication sold as Victoza for diabetes and Saxenda for weight loss. Doses, results, side effects, and how it compares to weekly options.
Zepbound Doses: All Six Strengths, the FDA Titration Schedule, and What Each One Does
All six Zepbound doses, the FDA-approved titration schedule, when each dose is used, and how the math compares to compounded tirzepatide.
Zepbound Dosing in 2026: The Full Schedule, Injection Technique, and Missed-Dose Rules
The full Zepbound dosing schedule, when to inject, what happens if you miss a dose, and how to handle dose escalation safely.
Mounjaro Doses: The Six Strengths, the Standard Titration Schedule, and How Providers Move You Up
Every Mounjaro dose from 2.5 mg to 15 mg, the standard titration schedule, what each step is for, and how providers decide when to move you up.
Under 60 seconds. Completely anonymous. Or start a consultation if you want a clinician to review what you're feeling.
This registry is for informational and research purposes only. Reports are self-submitted and unverified. Aggregate data is not a substitute for clinical diagnosis. Compounded medications are not FDA-approved as finished drug products. Consult a licensed healthcare provider before starting or changing any medication.